Teaming collaborations between diverse innovators are encouraged to help advance the development of a single-administration pandemic influenza A(H5N1) vaccine. Entrants interested in forming teams can fill out the teaming form to share a participant profile and connect with potential collaborators. Entrants can also take part in facilitated networking opportunities, like the September 29 Concept Stage Proposers’ Day.

Those who were unable to attend Proposers’ Day can still find potential collaborators. Entrant profiles will be available on this page for those looking to connect with others in the field. The page will be updated regularly throughout the open submissions period.

 

Teams

Select All That Apply

NanoVax Therapeutics

Worcester, MA

My team specializes in

AdjuvantsNovel delivery systems

Summary of core technology or service

NanoVax develops next-generation nanoparticle adjuvants combining STING and TLR4 agonists to boost influenza vaccine potency and complement diverse antigen platforms, enabling stronger, broader T-cell immunity.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Griffin Kane, PhD

Role

Chief Executive Officer

SaponiQx

Lexington MA

My team specializes in

Adjuvants

Summary of core technology or service

SaponiQx produces saponin adjuvants like QS-21 by plant cell culture rather than bark extraction. This enables production with greater scalability, consistency, and lower cost, allowing for their use in pandemic-scale vaccine programs that have been unable to benefit from their clinical profile historically.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMSEXCIPIENTS

Contact

Kaan Coffin

Role

Business Development

Contact email address

paul.coffin@agenusbio.com

Pharma Latch

Dublin, Ireland

My team specializes in

Novel delivery systems

Summary of core technology or service

Pharma Latch Hollow is a manufactured, single-use intradermal delivery device available now for evaluation. It connects to a standard syringe and uses proprietary microneedle geometry for reliable, technique-independent delivery to the dermis. We seek H5 antigen and adjuvant partners to explore controlled ID delivery for a single-administration pandemic influenza vaccine.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENT

Contact

Ronan Byrne

Role

CEO

Contact email address

ronan.byrne@latch-medical.com

Micron Biomedical, Inc.

Alpharetta, GA

My team specializes in

Novel delivery systems

Summary of core technology or service

Micron’s dissolvable microarray/microneedle patch platform enables painless, thermostable, self-administered vaccine delivery with customizable release profiles, demonstrated in Phase 1/2 trials and backed by commercial-scale manufacturing.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTADJUVANTS

Contact

Stephanie D. Adams, PhD

Role

Director, IP and Grant Management

Contact email address

sadams@micronbiomedical.com

BioVaxys Technology Corp.

Wayne, PA

My team specializes in

Novel delivery systems

Summary of core technology or service

The DPX platform presents antigens (proteins, peptides, VLPs, or polynucleotides) to the immune system using a novel non-systemic mechanism of action that drives APC pick-up of antigens at the site of the injection.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTADJUVANTS

Contact

Kenneth Kovan

Role

President & COO, BioVaxys

Contact email address

kkovan@biovaxys.com

Transmucosis

College Park, Maryland

My team specializes in

Novel delivery systemsAntigen developmentOther

Summary of core technology or service

We design the long-acting vaccines and delivery to enhance antigen presentation, antigen persistence, magnitude and durability of broad immune responses against different clades and subclades of H5N1 infections in a single administration.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Xiaoping Zhu

Role

Founder and CSO

Contact email address

xzhu@transmucosis.com

Apriori Bio

Somerville, MA

My team specializes in

Antigen development

Summary of core technology or service

Octavia™, Apriori's biology-enabled AI platform, predicts how pathogens will evolve and designs medical countermeasures engineered to elicit the ideal immune response in anticipation of that evolution

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Harry Kleanthous

Role

CSO

Contact email address

hkleanthous@aprioribio.com

Hexamer Therapeutics

Pullman Washington

My team specializes in

Antigen developmentNovel delivery systems

Summary of core technology or service

Hexamer has a self-assembling 100% peptide based hapten carrier with T-cell epitopes & ideally presented B-cells. A single shot COVID-19 vaccine had 165 days of durability in mice. It's Room Temp Stable and scalable manufacturing.

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Robert Bogden

Role

CEO

Contact email address

bogden@hexthera.com

Primrose Bio, Inc.

San Diego, CA USA

My team specializes in

Other

Summary of core technology or service

Accelerate vaccine development with Primrose Bio’s proven Pfenex Expression Technology®: a high-yield microbial platform for antigens, proteins, and VLPs from candidate screening through 100L PD. Used in 6 marketed products, including 4 vaccines.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Diane Retallack

Role

President and COO

Contact email address

diane@primrosebio.com

Battelle Biomedical Research Center

West Jefferson, Ohio

My team specializes in

Other

Summary of core technology or service

Battelle has decades of experience with influenza assay development, qualification, and validation and has supported dozens of pre-clinical and clinical influenza studies using epidemic, pre-pandemic (avian), and pandemic influenza viruses.

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Melicia Gainey

Role

Principal Investigator

Contact email address

gaineym@battelle.org

Wyss Institute at Harvard University

Boston, MA

My team specializes in

Novel delivery systems

Summary of core technology or service

We have developed injectable slow-release technologies that provide localized, controlled release of vaccine antigens and adjuvants. We are looking to partner with groups that have expertise in antigen/adjuvant development.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENT

Contact

Kwasi Adu-Berchie

Role

Senior Scientist, Immuno-materials

Coordify Solutions, LLC

Spring Brook TWP, PA

My team specializes in

Other

Summary of core technology or service

R&D Project Leadership, Strategy

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Tim Alefantis

Role

Founder & CEO

University of Virginia

Charlottesville, VA

My team specializes in

Antigen development

Summary of core technology or service

In our new recombinant bacteria platform, we use autotransporters to produce antigens closely resembling trimeric stalk regions, with added immunomodulators, creating new inactivated bacterial vaccines surface-expressing the antigens in ~3 weeks.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Steven Zeichner

Role

PI/Professor

Contact email address

zeichner@virginia.edu

POP Biotechnologies

Buffalo, NY

My team specializes in

AdjuvantsNovel delivery systems

Summary of core technology or service

Spontaneous nanoliposome-antigen particle system

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Jonathan Lovell

Role

CEO

Contact email address

jlovell@pop.bio

Website

pop.bio

Cassidy Cantin

Maryland

My team specializes in

Other

Summary of core technology or service

Sia/LBG delivers systems integration and program support backed by a 25+ member USG PMO and SMEs averaging 20+ years across regulatory, CMC, and MCM development, having secured $3.25B+ in government funding since 2020.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Cassidy B Cantin

Role

Associate Partner

Contact email address

ccantin@lathambiopharm.com

Valjuvant Corporation (Signl)

Chicago, IL

My team specializes in

OtherAdjuvants

Summary of core technology or service

Signl uses small molecules discovered from UChicago to tune the immune system. Our lead immunomodulators decouple reactogenicity from immunogenicity and boost the adaptive response in single dose applications (tested in hPBMCs, mice, ferrets, NHPs).

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Jeremiah Kim

Role

CSO / Co-founder

Contact email address

Jeremiah.kim@signlbio.com

AmerStem Inc

Camarillo, CA

My team specializes in

Adjuvants

Summary of core technology or service

AmerStem is developing SASCOM™, a next-generation ISCOM/Matrix-M-type Quillaja saponin adjuvant designed for stronger immunity, antigen dose-sparing, single-dose protection, scalable manufacturing, and long-term stockpiling

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Dr Jaime Flores Riveros

Role

Chief Scientific Officer

Contact email address

jfriveros@amerstem.com

Texas Biomedical Research Institute

San Antonio, Texas

My team specializes in

Other

Summary of core technology or service

H5N1 Ferret Challenge Model (see preprint @ https://www.biorxiv.org/content/10.64898/2026.08.10.744032v1). ABSL-3 and BSL-3 laboratories. Panel of neutralizing HA- and NA-directed H5N1 human mAbs. Faculty expertise in virology and immunology.

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Greg Ippolito

Role

Professor

Contact email address

gippolito@txbiomed.org

Boost Biopharma, Inc.

Boston, MA

My team specializes in

Antigen development

Summary of core technology or service

Boost Biopharma is a clinical-stage company that creates exceptional protein subunit antigens. We are interested in partnering on adjuvants and/or delivery technologies that have the potential to further improve our vaccines' single-dose performance.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Steve Gold

Role

CEO

Contact email address

steve@boostbiopharma.com

Vaccine Formulation Institute

Switzerland

My team specializes in

Adjuvants

Summary of core technology or service

VFI develops and supplies GMP-grade, open-access vaccine adjuvants based on emulsion and liposome technologies, combined with formulation expertise and technical, preclinical, regulatory and quality support for vaccine development.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Maria Lawrenz

Role

Operations Director

Contact email address

maria.lawrenz@vformulation.org

Nebraska Center for Virology

Lincoln, NE

My team specializes in

Antigen development

Summary of core technology or service

We integrate a systems approach that combines bioinformatics, phylogenetics, immunology, and molecular biology to design rapid, durable, cross-protective vaccines.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

NOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Eric Weaver

Role

Director

Contact email address

eweaver2@unl.edu

OmniPulse Biosciences, Inc.

Cambridge, MA

My team specializes in

Novel delivery systems

Summary of core technology or service

We have a highly scalable, pulsatile-release injectable platform. A single injection delivers multiple, time-released doses — eliminating the need for follow-up boosters. Co-formulation is not required. We can manufacture clinical product in-house.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENT

Contact

Bob Farra

Role

CTO

Contact email address

rfarra@omnipulsebio.com

Advanced BioScience Laboratories (ABL, Inc.)

Rockville, MD

My team specializes in

Other

Summary of core technology or service

cGMP production and testing of products from preclinical, clinical, to commercial phase in both adherent and suspension systems. Our experience includes multiple modalities including live virus, viral vectors, subunits, nanoparticles, and others.

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Timothy R Fouts

Role

CSO

Contact email address

timothy.fouts@ablinc.com

University of Maryland, Baltimore

Baltimore, Maryland, USA

My team specializes in

Antigen development

Summary of core technology or service

My lab has capacity to design, express and purify recombinant proteins in mammalian cells. We have extensive experience with influenza hemagglutinin (HA), including avian H5. We currently have an inventory of over 30 H5 strains, spanning all clades.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Lynda Coughlan

Role

Associate Professor and Principal Investigator

Contact email address

lcoughlan@som.umaryland.edu

HDT Bio

Seattle, WA

My team specializes in

AdjuvantsNovel delivery systems

Summary of core technology or service

HDT Bio's LION™ technology is a GMP and clinically validated delivery platform that enables co-delivery of adjuvants to simultaneously target orthogonal pathways, including RIG-I and multiple TLRs (TLR3/4/7/8)

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Amit Khandhar

Role

Director, Formulations

Contact email address

amit.khandhar@hdt.bio

American Type Culture Collection

Manassas, VA

My team specializes in

OtherAntigen developmentNovel delivery systems

Summary of core technology or service

Providing biological resource expertise, characterized virus stocks, custom reference materials, cGMP-compliant biorepository services, and production capabilities that help innovators de-risk, validate, and accelerate pandemic countermeasures.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Eldar Imanverdi

Role

Senior Director, Business Development

Contact email address

eimanverdi@atcc.org

Uvax Bio, LLC

Dover, Delaware, U.S.A.

My team specializes in

Antigen developmentNovel delivery systems

Summary of core technology or service

Multilayered, stable protein nanoparticle scaffold displaying multimeric array of PF stabilized H5N1 HA trimers

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENT

Contact

Kevin O'Neill

Role

Chief Executive Officer

Contact email address

kevin.oneill@uvaxbio.com

TollereBio

USA

My team specializes in

Adjuvants

Summary of core technology or service

TollereBio's BECC adjuvant technology offers best in class, rationally designed, fully synthetic TLR4 agonist adjuvants backed by pre-clinical data.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Hans Lien

Role

COO

Contact email address

hans.lien@tollerebio.com

LTS Lohmann

Germany, US

My team specializes in

Novel delivery systems

Summary of core technology or service

LTS’s proprietary AccuTip dissolvable microneedle patch combines novel vaccine delivery, manufacturing-ready scale-up, and deep experience across a variety of actives—enabling rapid adaptation to virtually any vaccine for the Single Shield Prize.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

May Pidding

Role

Global Strategic Product Management

Contact email address

may.pidding@ltslohmann.com

Texas Biomedical Research Institute

San Antonio, Texas

My team specializes in

Other

Summary of core technology or service

Our team can provide integrated preclinical evaluation of vaccine candidates, from immunization to challenge and transmission studies through immunological, virological, and pathological characterization using mice, guinea pigs, ferrets, and NHP.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Luis Martinez-Sobrido

Role

Principal Investigator

Contact email address

lmartinez@txbiomed.org

Codagenix Inc.

New York, USA

My team specializes in

Antigen development

Summary of core technology or service

We discover and develop live virus vaccines for A/H5N1 that can be inactivated and/or adjuvanted with novel agents to be responsive to this Prize and are looking for partners including biomarker partners to demonstrate safety and efficacy

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Jeffrey Fu

Role

Chief Business Officer

Contact email address

jfu@codagenix.com

VisMederi America Corp.

Cleveland, OH

My team specializes in

Other

Summary of core technology or service

Pre-clinical services to include immunogenicity and efficacy evaluations Bioanalytical support using validated influenza assays for pre-clinical and clinical studies

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Brian Price

Role

President

Photosynthetic B.V.

Amsterdam, The Netherlands

My team specializes in

Novel delivery systemsOther

Summary of core technology or service

Photosynthetic develops a high-resolution volumetric printing platform for rapid microfabrication. The technology enables complex polymer microstructures, including microneedle arrays and other vaccine-delivery components, with micron-scale precision

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

EXCIPIENTSANTIGEN DEVELOPMENTADJUVANTS

Contact

Magdalena Kurzyp

Role

CBO

Contact email address

magdalena@photosynthetic.nl

Vaxine Inc

Colorado

My team specializes in

AdjuvantsAntigen developmentNovel delivery systems

Summary of core technology or service

Vaxine specialises in development of new adjuvants targetting DC-SIGN (Advax delta inulin adjuvant), TLR9 (CpG55.2) as well as having candidate compounds targeting TLR2, TLR4, TLR7/8 and NOD2. It also has expertise in antigen design and delivery.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

NOVEL DELIVERY SYSTEMSANTIGEN DEVELOPMENT

Contact

Nikolai Petrovsky

Role

Research Director

Contact email address

nikolai.petrovsky@vaxine.net

Website

vaxine.net

Texas Children's Ctr for Vaccine Development, Baylor College Med

Houston, TX, USA

My team specializes in

Antigen developmentOtherAdjuvants

Summary of core technology or service

We develop recombinant protein vaccines against viruses, with experience in technology transfer, QA/RA systems, and IND submissions to the US FDA supporting translation from discovery through clinical readiness.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Ulrich Strych

Role

Director for Strategic Initiatives and Program Development

Contact email address

strych@bcm.edu

Vaxxas Pty Ltd

Brisbane, Queensland, Australia

My team specializes in

Novel delivery systems

Summary of core technology or service

The high-density microarray patch (HD-MAP) is a needle-free vaccine delivery platform for skin-based vaccine delivery. Potential benefits: enhanced immune response, antigen dose-sparing, improved thermostability, and simplified administration.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Elouise Comber

Role

Business Development

Contact email address

ecomber@vaxxas.com

DEKA

Manchester, NH

My team specializes in

Novel delivery systems

Summary of core technology or service

Self-administrable, intradermal vaccine applicator

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Fareena

Role

VP - Strategy & Commercialization

Contact email address

fareena@dekaresearch.com

Now accepting Declarations of Intent